Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia

Inclusion Criteria: * Presence of radiological evidence of a new or progressive infiltrate(s) consistent with bacterial pneumonia and at least 2 of the following: * Productive cough with purulent or mucopurulent sputum/tracheobronchial secretions or change in the character of sputum (increased volume or purulence) * Dyspnea or tachypnea * Rigors or chills- Pleuritic chest pain * Auscultatory findings on pulmonary examination of rales/crackles and/or evidence of pulmonary consolidation- Fever or hypothermia * White blood cell count \>/= 10000/mm3 or \>/= 15% immature neutrophils, regardless of the peripheral WBC count, or leukopenia with total WBC count \< 4500/mm3 Exclusion Criteria: * Known hypersensitivity to fluoroquinolones- Presence of end-organ damage or shock with need for vasopressors for \> 4 hours at the time of study entry * Need for mechanical ventilation at study entry * Implanted cardiac defibrillator.- Significant bradycardia with heart rate \< 50 beats/minute. * Hospitalized for \> 48 hours before developing pneumonia. * Systemic antibacterial therapy for more than 24 hours within 7 days of enrollment unless the patient was deemed a treatment failure after receiving greater than 72 hours of a non-fluoroquinolone antibiotic. * Co-existent disease considered likely to affect the outcome of the study (e.g. active lung cancer, connective tissue disease affecting the lungs, bronchiectasis). * Mechanical endobronchial obstruction (e.g. endobronchial tumor). * Known or suspected active tuberculosis or endemic fungal infection * Neutropenia (neutrophil count \< 1000/Microliter). * Chronic treatment (equal or longer than 2 weeks) with known immunosuppressant therapy (including treatment with \> 15 mg/day of systemic prednisone or equivalent). * Patient with known HIV infection and a CD4 count \< 200/mm3 . * Known severe hepatic insufficiency . * Renal impairment with a baseline measured or calculated serum creatinine clearance \< 20 mL/min. If a recent value for a 24 hour creatinine clearance is not available then the creatinine clearance should be calculated using the Cockcroft-Gault formula . * Known prolongation of the QT interval or use of Class IA or Class III antiarrhythmics (e.g., quinidine, procainamide, amiodarone, sotalol). * Uncorrected hypokalemia. * Previous history of tendinopathy with quinolones. * Previously entered in this study.- Participated in any clinical investigational drug study within 4 weeks of screening. * Known or suspected concomitant bacterial infection requiring additional systemic antibacterial treatment. * Patients with a history of a hypersensitivity reaction to multivitamin infusion (MVI) or pre-existing hypervitaminosis.